Streetbeat News

FBRX

Forte Biosciences, Inc.

https://www.fortebiorx.com

Industry

Biotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Open

24.64

Mkt cap

34M

Volume

56K

High

24.64

P/E Ratio

-1.41

52-wk high

28.68

Low

21.57

Div yield

N/A

52-wk low

4.11

Forte Biosciences (FBRX) is highlighted as a strong candidate for short-term investors due to its recent positive price momentum and solid fundamentals. The stock has been identified through a trading strategy-based screen.

Portfolio Pulse from

November 28, 2024 | 3:00 pm

Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects.

Portfolio Pulse from

November 19, 2024 | 6:15 pm

Several health care stocks experienced significant price movements during Thursday's intraday session. Notable gainers included Pasithea Therapeutics, Telesis Bio, and Adaptive Biotechnologies, while Inventiva and Theriva Biologics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:31 pm

Trading for FBRX was halted at 7:50:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.